WO2022077087A1 - Microssuspensão contra parasitas e método para sua obtenção - Google Patents
Microssuspensão contra parasitas e método para sua obtenção Download PDFInfo
- Publication number
- WO2022077087A1 WO2022077087A1 PCT/BR2021/050447 BR2021050447W WO2022077087A1 WO 2022077087 A1 WO2022077087 A1 WO 2022077087A1 BR 2021050447 W BR2021050447 W BR 2021050447W WO 2022077087 A1 WO2022077087 A1 WO 2022077087A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microsuspension
- against parasites
- doramectin
- albendazole sulfoxide
- hydroxybenzoate
- Prior art date
Links
- 244000045947 parasite Species 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 12
- 229950010075 albendazole sulfoxide Drugs 0.000 claims abstract description 47
- VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000002245 particle Substances 0.000 claims abstract description 19
- 150000002596 lactones Chemical class 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 51
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 229960003997 doramectin Drugs 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 21
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 14
- 235000013772 propylene glycol Nutrition 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 11
- 229940074076 glycerol formal Drugs 0.000 claims description 11
- 239000002202 Polyethylene glycol Chemical class 0.000 claims description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Chemical class 0.000 claims description 10
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 10
- 238000013019 agitation Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Chemical class OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- 239000000600 sorbitol Chemical class 0.000 claims description 8
- 239000005660 Abamectin Substances 0.000 claims description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 150000004702 methyl esters Chemical class 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 5
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 5
- 229960002418 ivermectin Drugs 0.000 claims description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 claims description 2
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims description 2
- 239000004251 Ammonium lactate Substances 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000011703 D-panthenol Substances 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- 235000004866 D-panthenol Nutrition 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Chemical class 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Chemical class 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Chemical class 0.000 claims description 2
- 229950008167 abamectin Drugs 0.000 claims description 2
- 229940059265 ammonium lactate Drugs 0.000 claims description 2
- 235000019286 ammonium lactate Nutrition 0.000 claims description 2
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims description 2
- 229960002903 benzyl benzoate Drugs 0.000 claims description 2
- 229930188620 butyrolactone Natural products 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229960003949 dexpanthenol Drugs 0.000 claims description 2
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims description 2
- 229960002346 eprinomectin Drugs 0.000 claims description 2
- -1 glycerolformal Chemical compound 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 2
- 229960004816 moxidectin Drugs 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 229920006163 vinyl copolymer Chemical class 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 13
- 238000009472 formulation Methods 0.000 description 30
- 239000012071 phase Substances 0.000 description 20
- 241000244206 Nematoda Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000007931 macrolactones Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000383197 Cooperia punctata Species 0.000 description 3
- 241000243976 Haemonchus Species 0.000 description 3
- 241001137882 Nematodirus Species 0.000 description 3
- 241000510958 Oesophagostomum radiatum Species 0.000 description 3
- 241000243794 Ostertagia ostertagi Species 0.000 description 3
- 241001674048 Phthiraptera Species 0.000 description 3
- 241000509427 Sarcoptes scabiei Species 0.000 description 3
- 241000869417 Trematodes Species 0.000 description 3
- 241000534450 Viviparus Species 0.000 description 3
- 244000079386 endoparasite Species 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000000590 parasiticidal effect Effects 0.000 description 3
- 239000002297 parasiticide Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- 241000242722 Cestoda Species 0.000 description 2
- 241001306565 Cooperia pectinata Species 0.000 description 2
- 241000202828 Dermatobia hominis Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001137878 Moniezia Species 0.000 description 2
- 241000244159 Taenia saginata Species 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 244000078703 ectoparasite Species 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 241000415078 Anemone hepatica Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000238678 Boophilus Species 0.000 description 1
- 241000931178 Bunostomum Species 0.000 description 1
- 241001266304 Bunostomum phlebotomum Species 0.000 description 1
- 241000253350 Capillaria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000893172 Chabertia Species 0.000 description 1
- 241001307956 Chorioptes bovis Species 0.000 description 1
- 241000202814 Cochliomyia hominivorax Species 0.000 description 1
- 241001126268 Cooperia Species 0.000 description 1
- 241001126267 Cooperia oncophora Species 0.000 description 1
- 241000876444 Cooperia surnabada Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000894055 Haematopinus eurysternus Species 0.000 description 1
- 241000243992 Haemonchus placei Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000543830 Hypoderma bovis Species 0.000 description 1
- 241000257174 Hypoderma lineatum Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001113970 Linognathus Species 0.000 description 1
- 241000403354 Microplus Species 0.000 description 1
- 241001137879 Moniezia expansa Species 0.000 description 1
- 241000510960 Oesophagostomum Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001649230 Psoroptes ovis Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000044136 Solenopotes Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical class CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000001793 endectocide Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
- A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
- A01N47/18—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof containing a —O—CO—N< group, or a thio analogue thereof, directly attached to a heterocyclic or cycloaliphatic ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P5/00—Nematocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Definitions
- the present invention deals with a microsuspension against parasites in animals and its method of preparation, more particularly intended for the veterinary industry.
- the benzoimidazoles have their structure characterized by being a bicycle composed of a benzene ring and an imidazole ring, as shown in Formula 1 below.
- veterinary pharmaceutical formulations containing albendazole sulfoxide in the form of hydrochloride present stability problems, as it degrades over time, forming undesirable by-products, in addition to losing the potency of the active, especially if there is associated water. to the formulation (WU, 2009).
- Cyclodextrins also appear as an aid to increase the solubility of ricobendazole, and these complexes and injectable formulations form the descriptions of patent W02006022562.
- Doramectin (Formula 3) is a potent second-rate endectocide. generation of the avermectin family and has been used for the treatment of endoparasites, nematodes and ectoparasites of insects, lice and ticks in cattle (GOUDIE, 1993). In commercial formulations it has been widely used and used extensively in oral and pour-on forms.
- Patent BR9406627 presents a composition of association of particulate albendazole sulfoxide or others, added to macrolactones, for oral administration, having casein and/or gelatin as a dispersant,
- BR102013031277 represents a recent attempt to formulate the product combination ivermectin and albendazole sulfoxide.
- this formulation comprises use of dimethyl sulfoxide as solvent, N-methyl-2-pyrrolidone carrier and ethyl alcohol as permeation agent.
- This formulation does not disclose the use of a dispersing agent, suspending agent or surfactant.
- the association of doramectin and albendazole sulfoxide is poorly studied and consists of an association that combines the action of albendazole sulfoxide against the main gastrointestinal and pulmonary verminoses (nematodes) that affect cattle, in addition to tapeworms (tapeworms) ), Cysticercus bovis (Taenia saginata embryo), Moniezia expansae trematode (adult fasciolae). It has action against the 3 phases of the life cycle of the parasites (adults, larvae - including hypobiotic and eggs).
- Gastrointestinal nematodes Haemonchus spp., Trichostrongyius axei, Strongyioides spp., Cooperia spp., Oesophagostomum spp., Nematodirus spp., Chabertia spp., Bunostomum spp., Capillaria spp.
- Lung nematodes Dictyocalus spp.
- Cestodes Moniezia spp.
- Trematodes Fasdoia hepatica
- Cysticercus Cysticercus bovis (Taenia saginata embryo).
- Doramectin targets the following parasites: Gastrointestinal nematodes (adults and L4 larvae): Ostertagia ostertagi (including inhibited larvae), Haemonchus placei, Tr ⁇ chostrongyius axei, Tcoiubriformis, Cooperia oncophora, C, pectinate, C.punctata, C.surnabada (syn. mcmasteri) ), Nematodirus spathigeg Bunostomum phlebotomum, Strongyioides papillosus, Oesophagostomum radiatum, Trichuris spp.
- Lung nematodes (adults and L4 larvae): Dictyocauius viviparus. Eye nematodes (adults: Theiazia spp. Muscid larvae: (parasitic stages): Hypoderma bovis, H.lineatum. Sucking lice: Haematopinus eurysternus, Linognathus vitulio Solenopotes capHiatus. Scabies mites: Psoroptes bovis, Sarcoptes scabiei.
- Nematodirus heivetianus biting lice (Damaiinia bovis), ticks (Rhipicephaius (Boophilus) microplus) and scabies mites Chorioptes bovis, Dermatobia hominis and Cochliomyia hominivorax larvae. of these two substances can be indicated as parasiticide in the treatment of cattle, sheep and goats.
- the objective was to develop an invention that dealt with a composition of a macrocidic lactone and albendazole sulfoxide constituting an effective injectable veterinary dosage form, involving only a few exdpientes, but that had good resuspension, good viscosity, good syringeability , excellent stability and useful life, thus allowing greater anti-parasitic efficacy, being also commercially viable.
- the present invention describes a simple and applicable method for preparing a stable microsuspended veterinary pharmaceutical form, comprising macrocid lactone and albendazole sulfoxide having an average particle size of D 50 ⁇ 250 ⁇ m.
- This invention deals with a new veterinary product from the association of avermectin and benzoimidazole, more specifically, between doramectin and albendazole sulfoxide to combat parasites that attack animals.
- This product is a stable injectable microsuspended pharmaceutical formulation.
- the process of the present invention consists of preparing a specific organic solvent system at room temperature, dissolving in it the macrocidic lactone, preferably doramectin, and then adding the albendazole sulfoxide, under agitation with frequency between 150 to 600 r.p.m.
- the present invention presents an easy and simple way to prepare the formulation, in which, as it is a stable microsuspension, it avoids precipitation of the active albendazole sulfoxide in the form of undesirable granules that could alter the resuspensibility and consequently interfere with the average dose injected into the animal.
- This formulation also, being stable and micro-suspended, provides excellent syringeability, resulting in shorter handling time, absence of syringe clogging and less stress for the animals to be treated.
- the present invention overcomes this obstacle by presenting a pharmaceutical form with slow release, using benzimidazole, at neutral pH, avoiding such problems described above. Furthermore, the present invention guarantees the chemical stability of doramectin, as it is known that macrocidic lactones can easily undergo hydrolysis, especially at acidic pH. Thus, this invention also solves the problem of macrolactone loss of potency over its shelf life.
- the present invention solves the problem of incompatibility and chemical degradation of active principles (albendazole sulfoxide and doramectin) through the correct choice and association of excipients, in addition to providing a pharmaceutical form with safe and prolonged effective.
- active principles albendazole sulfoxide and doramectin
- the formulation is physically and chemically stable, excluding water, with a pH compatible with the tissue, allowing two actives to coexist with stability in different phases.
- the parasiticide microsuspension according to the invention comprises, in mass in relation to the total mass of the composition, the components below:
- the macrocidic lactones according to the invention can be chosen from the group comprising: doramectin, moxidectin, ivermectin, abamectin, eprinomectin and others, or even mixtures thereof. Preferably doramectin is used.
- Solvents for preparing the formulation of this invention can be chosen from the group of hexylene glycol, acetone, isopropanol, methyl ester, N-dimethylacetamide, acetonitrile, dipropylene glycol monomethyl ether, butyrolactone, glycerolphoral, benzyl benzoate, N-methyl -2-pyrrolidone, triacetin.
- glycerolformal and/or methyl ester are used.
- the viscosity agents can be chosen from glycerin, gelatin, collagen, propylene glycol, ammonium lactate, butylene glycol and D-panthenol.
- glycerin and/or propylene glycol are used.
- the suspension stabilizing agents used in this invention can be selected from vinylpyrrolidone, sorbitol, carbopol, hydroxyethylcellulose, vinyl copolymers, macrogol derivatives, polyethylene glycol derivatives.
- polyethylene glycol derivatives are used, more preferably PEG-400 and/or PEG-200 and/or sorbitol.
- the preservatives contained in the formulation can be chosen from the class of parabens, particularly propyl and/or methyl p-hydroxybenzoate.
- the present invention describes a simple and applicable method for preparing a stable microsuspension veterinary pharmaceutical form, where the macrocyclic lactone is in solution, the albendazole sulfoxide is in suspension having an average effective particle size of D 50 ⁇ 250 ⁇ m, preferably D 50 ⁇ 100 ⁇ m, more preferably D 50 ⁇ 50 ⁇ m and even more preferably D 50 25 ⁇ m.
- the pharmaceutical form prepared has a viscosity between 10-100 cP, preferably 20 to 50cP.
- the microsuspension formulation according to the Invention comprises, in mass in relation to the total mass of the composition, the following components:
- polyethylene glycol preferably PEG-200
- the microsuspension formulation according to the invention comprises, in mass in relation to the total mass of the composition, the following components:
- the microsuspension according to the invention comprises, by mass in relation to the total mass of the composition, the following components:
- polyethylene glycol preferably PEG-400
- the microsuspension according to the invention comprises, by mass in relation to the total mass of the composition, the following components: - doramectin from 0.5 to 10.0%;
- polyethylene glycol preferably PEG-400
- ABZSO is an abbreviation for the name albendazole sulfoxide
- Another aspect that pertains to this invention is the viscosity acceptability of the formulation. Obeying the preparation of the pharmaceutical formulation, it will present excellent syringability, which is the ability of a product to be successfully administered through an appropriate syringe and needle.
- the optimal syringeability is dependent on the viscosity of the solution and the size of the particles, which are usually measured by laser diffraction, and are measured in micrometers or nanometers.
- D 50 is the average particle diameter.
- the prepared formulation is intended for the treatment and prevention of parasites caused by endo and ectoparasites, administered subcutaneously.
- the average size of the particles must be less than 100 micrometers, and may vary between 1 to 50 micrometers.
- the preparation process of the present invention consists of preparing a specific organic solvent system at room temperature, dissolving the doramectin in it and then adding the albendazole sulfoxide, under constant stirring.
- the way of preparing the pharmaceutical formulation is simple and easy to perform. In order to obtain said formulation, it is necessary to subject the albendazole sulfoxide to micronization before carrying out the preparation of the formulation.
- Such steps for the preparation of the injectable pharmaceutical formulation take place at room temperature and are described below: a) under agitation, one or more solvents, the viscosity agent and the suspension stabilizer are mixed. ; b) after filtering the solution obtained in the previous step, the preservatives are dissolved under stirring until complete dissolution; c) the macrocid lactone is then dissolved in the liquid mixture obtained in step c) with stirring until complete dissolution, followed by filtration; d) under constant stirring, sterilized micronised albendazole sulfoxide with particles of average size D 50 ⁇ 250 ⁇ m, preferably D 50 ⁇ 50 ⁇ m, is added, maintaining constant stirring until the final suspension is obtained.
- the method of obtaining the microsuspension has the following steps: a) under agitation from 150 to 600 rpm, the solvent, the viscosity agent and the suspension stabilizer are mixed in a suitable reactor ; b) after filtering the solution obtained in the previous step, the preservatives are dissolved under stirring until complete dissolution; c) the doramectin is then dissolved in the liquid mixture obtained in step c) with stirring until complete dissolution, followed by filtration; d) under constant stirring, micronised albendazole sulfoxide is added with particles of average size D 50 ⁇ 250 ⁇ m, preferably D 50 ⁇ 50 ⁇ m, maintaining constant stirring until the final suspension is obtained.
- formulations according to the invention are suitable for low injection volume, such as ImL for 50kg of animal body weight.
- the formulation according to the invention proved to be effective against: Ostertagia ostertagi, Cooperia pectinata, Cooperia punctata, Trichostrongyius axei. Trichostrongyius coiubriformis, Oesophagostomum radiatum, Haemonchus piacei, Dictyocauius viviparus.e Moniezia expansa and doramectin which is effective against endoparasites: Ostertagia ostertagi, Cooperia pectinata, Cooperia punctata, Tridiostrongyius axei, Tridiostrongyius coiubriformis, Oesophagostomum radiatum, Haemonchus p/acei and Dictyocau/us viviparus and the edoparasites: Dermatobia hominis, larvae of Cochiiornyia hominivorax and Rhipicephaius (B
- Phase I In a vessel under agitation with rotation of 300 r.p.m., 73.2 kg of glycerolformal were added; 31.08 kg of propylene glycol and 11.30 kg of PEG-400. Stirring was maintained at 300 r.p.m. for 30 minutes.
- Phase III Under constant stirring at 300 rpm, 10.0 kg of sterile micronised albendazole sulfoxide with particle size D 50 ⁇ 3.3 ⁇ m were loaded onto Phase II. An additional 24.40 kg of the Phase I solution was charged. It was stirred at 300 rpm for 30 minutes, thus obtaining the final suspension.
- Phase I In a vessel under agitation with a rotation of 300 r.p.m., 71.80 kg of glycerolformal were added; 23.5 kg of glycerin and 16.3 kg of Sorbitol. Stirring was maintained at 300 r.p.m. for 30 minutes.
- Phase II 80 kg obtained in Phase I were filtered through a 0.2 ⁇ m filter and 100 g of methyl p-hydroxybenzoate and 10 g of propyl p-hydroxybenzoate were added, being stirred until complete dissolution. Then 1.06 kg of doramectin was added and stirred at 300 rpm until complete dissolution and filtration through a 0.2 ⁇ m filter.
- Phase I In a vessel under agitation with rotation of 300 r.p.m., 50.20 kg of methyl ester were added; 23.5 kg of propylene glycol and 16.3 kg of sorbitol. Stirring was maintained at 300 r.p.m. for 30 minutes.
- Phase II 80 kg obtained in Phase I were filtered through a 0.2 ⁇ m filter and 100 g of methyl p-hydroxybenzoate and 10 g of propyl p-hydroxybenzoate were added, being stirred until complete dissolution. Then 1.06 kg of doramectin was added and stirred at 300 r.p.m. until complete dissolution and filtration through a 0.2 ⁇ m filter.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21878806.5A EP4230203A1 (en) | 2020-10-16 | 2021-10-14 | Microsuspension against parasites and method for obtaining same |
US18/031,942 US20240000752A1 (en) | 2020-10-16 | 2021-10-14 | Microsuspension against parasites and method for obtaining same |
AU2021361343A AU2021361343A1 (en) | 2020-10-16 | 2021-10-14 | Microsuspension against parasites and method for obtaining same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102020021181-1A BR102020021181A2 (pt) | 2020-10-16 | 2020-10-16 | Microssuspensão contra parasitas e método para sua obtenção |
BRBR1020200211811 | 2020-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022077087A1 true WO2022077087A1 (pt) | 2022-04-21 |
Family
ID=81207349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2021/050447 WO2022077087A1 (pt) | 2020-10-16 | 2021-10-14 | Microssuspensão contra parasitas e método para sua obtenção |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240000752A1 (pt) |
EP (1) | EP4230203A1 (pt) |
AR (1) | AR123832A1 (pt) |
AU (1) | AU2021361343A1 (pt) |
BR (1) | BR102020021181A2 (pt) |
UY (1) | UY39463A (pt) |
WO (1) | WO2022077087A1 (pt) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915986A (en) | 1974-06-19 | 1975-10-28 | Smithkline Corp | Methyl 5-propylthio-2-benzimidazolecarbamate |
GB2025223A (en) | 1978-07-17 | 1980-01-23 | Syntex Inc | Injectable anthelmintic benzimidazole compositions |
BR9406627A (pt) | 1993-05-26 | 1996-02-06 | Commw Scient Ind Res Org | Composições antiparasiticas |
EP0919231A1 (en) | 1997-10-15 | 1999-06-02 | Biogenesis, S.A. | Injectable parasiticide composition and process for the preparation |
WO2006022562A1 (en) | 2004-08-26 | 2006-03-02 | Bomac Research Limited | Improved chemical delivery formulations |
NZ567991A (en) * | 2005-12-06 | 2010-07-30 | Wyeth Corp | Benzimidazole non-aqueous compositions |
CN101984958A (zh) * | 2010-11-01 | 2011-03-16 | 新疆医科大学第一附属医院 | 纳米级阿苯达唑微粉及其制备方法 |
US20120213830A1 (en) * | 2006-06-14 | 2012-08-23 | Carsten Schmidt | Suspension comprising benzimidazole carbamate and a polysorbate |
AU2013205280A1 (en) * | 2012-04-19 | 2013-11-07 | Alleva Animal Health Limited | Macrocyclic Lactone injectable Formulations |
CN103800355A (zh) * | 2014-02-26 | 2014-05-21 | 江苏斯威森生物医药工程研究中心有限公司 | 一种含伊维菌素、丙硫亚砜和吡喹酮复方长效微球驱虫药 |
NZ619290A (en) * | 2010-12-08 | 2015-04-24 | Jurox Pty Ltd | Anthelmintic formulation |
BR102013031277A2 (pt) | 2013-12-05 | 2015-11-10 | Ouro Fino Participaç Es E Empreendimentos S A | processo para preparar uma composição anti-helmíntica, composição anti-helmíntica, método de tratamento veterinário e método de tratamento anti-helmíntico |
BG2358U1 (bg) * | 2016-03-23 | 2016-12-30 | "Ендектовет" Еоод | Антихелминтно средство |
CN106389456A (zh) * | 2016-11-16 | 2017-02-15 | 佛山市正典生物技术有限公司 | 一种兽用阿苯达唑伊维菌素预混剂及其制备方法 |
RU2732293C1 (ru) * | 2019-11-26 | 2020-09-15 | Федеральное государственное бюджетное научное учреждение "Федеральный научный центр - Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. К.И. Скрябина и Я.Р. Коваленко" (ФГБНУ ФНЦ ВИЭВ РАН) | Супрамолекулярный антигельминтный комплекс для лечения и профилактики животных при основных гельминтозах |
-
2020
- 2020-10-16 BR BR102020021181-1A patent/BR102020021181A2/pt unknown
-
2021
- 2021-10-08 UY UY0001039463A patent/UY39463A/es unknown
- 2021-10-14 US US18/031,942 patent/US20240000752A1/en active Pending
- 2021-10-14 EP EP21878806.5A patent/EP4230203A1/en active Pending
- 2021-10-14 WO PCT/BR2021/050447 patent/WO2022077087A1/pt active Application Filing
- 2021-10-14 AU AU2021361343A patent/AU2021361343A1/en active Pending
- 2021-10-15 AR ARP210102864A patent/AR123832A1/es unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915986A (en) | 1974-06-19 | 1975-10-28 | Smithkline Corp | Methyl 5-propylthio-2-benzimidazolecarbamate |
GB2025223A (en) | 1978-07-17 | 1980-01-23 | Syntex Inc | Injectable anthelmintic benzimidazole compositions |
BR9406627A (pt) | 1993-05-26 | 1996-02-06 | Commw Scient Ind Res Org | Composições antiparasiticas |
EP0919231A1 (en) | 1997-10-15 | 1999-06-02 | Biogenesis, S.A. | Injectable parasiticide composition and process for the preparation |
WO2006022562A1 (en) | 2004-08-26 | 2006-03-02 | Bomac Research Limited | Improved chemical delivery formulations |
NZ567991A (en) * | 2005-12-06 | 2010-07-30 | Wyeth Corp | Benzimidazole non-aqueous compositions |
US20120213830A1 (en) * | 2006-06-14 | 2012-08-23 | Carsten Schmidt | Suspension comprising benzimidazole carbamate and a polysorbate |
CN101984958A (zh) * | 2010-11-01 | 2011-03-16 | 新疆医科大学第一附属医院 | 纳米级阿苯达唑微粉及其制备方法 |
NZ619290A (en) * | 2010-12-08 | 2015-04-24 | Jurox Pty Ltd | Anthelmintic formulation |
AU2013205280A1 (en) * | 2012-04-19 | 2013-11-07 | Alleva Animal Health Limited | Macrocyclic Lactone injectable Formulations |
BR102013031277A2 (pt) | 2013-12-05 | 2015-11-10 | Ouro Fino Participaç Es E Empreendimentos S A | processo para preparar uma composição anti-helmíntica, composição anti-helmíntica, método de tratamento veterinário e método de tratamento anti-helmíntico |
CN103800355A (zh) * | 2014-02-26 | 2014-05-21 | 江苏斯威森生物医药工程研究中心有限公司 | 一种含伊维菌素、丙硫亚砜和吡喹酮复方长效微球驱虫药 |
BG2358U1 (bg) * | 2016-03-23 | 2016-12-30 | "Ендектовет" Еоод | Антихелминтно средство |
CN106389456A (zh) * | 2016-11-16 | 2017-02-15 | 佛山市正典生物技术有限公司 | 一种兽用阿苯达唑伊维菌素预混剂及其制备方法 |
RU2732293C1 (ru) * | 2019-11-26 | 2020-09-15 | Федеральное государственное бюджетное научное учреждение "Федеральный научный центр - Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. К.И. Скрябина и Я.Р. Коваленко" (ФГБНУ ФНЦ ВИЭВ РАН) | Супрамолекулярный антигельминтный комплекс для лечения и профилактики животных при основных гельминтозах |
Non-Patent Citations (1)
Title |
---|
EDMONDS M.D., VATTA A.F., MARCHIONDO A.A., VANIMISETTI H.B., EDMONDS J.D.: "Concurrent treatment with a macrocyclic lactone and benzimidazole provides season long performance advantages in grazing cattle harboring macrocyclic lactone resistant nematodes", VETERINARY PARASITOLOGY, ELSEVIER SCIENCE, AMSTERDAM., NL, vol. 252, 15 March 2018 (2018-03-15), NL , pages 157 - 162, XP055932870, ISSN: 0304-4017, DOI: 10.1016/j.vetpar.2018.02.009 * |
Also Published As
Publication number | Publication date |
---|---|
AU2021361343A1 (en) | 2023-06-08 |
UY39463A (es) | 2022-05-31 |
AR123832A1 (es) | 2023-01-18 |
BR102020021181A2 (pt) | 2022-04-26 |
US20240000752A1 (en) | 2024-01-04 |
EP4230203A1 (en) | 2023-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960005705B1 (ko) | 플로르페니콜의 약제학적 조성물 | |
BRPI0409185B1 (pt) | Formulações veterinárias anti-helmínticas tópicas | |
US5773422A (en) | Avermectin formulation | |
BR0307974B1 (pt) | composição parasiticida de ação prolongada contendo um composto de salicilanilida, uma espécie polimérica e pelo menos um outro composto antiparasita | |
BRPI0819849B1 (pt) | sistemas de solvente para formulações pour on para combater parasitas | |
US20220296564A1 (en) | Injectable pharmaceutical compositions and uses thereof | |
CN106132409B (zh) | 稳定的兽用驱虫制剂 | |
JP5342239B2 (ja) | ベンジイミダゾール非水性組成物 | |
BRPI0312814B1 (pt) | levamisol / avermectinas ou similares em solvente de pirrolidona | |
BR122023023401A2 (pt) | Composição farmacêutica injetável, usos de um composto isoxazolina e kit compreendendo o referido composto | |
WO2015081401A1 (pt) | Processo para preparar uma composição anti-helmíntica, composição anti-helmíntica, método de tratamento veterinário e método de tratamento anti-helmíntico | |
WO2022077087A1 (pt) | Microssuspensão contra parasitas e método para sua obtenção | |
PT1713468E (pt) | Composição anti-helmíntica | |
AU2022268378A1 (en) | Injectable formulation of a macrocyclic lactone and levamisole | |
PT1646425E (pt) | Composição parasiticida | |
BR112020012465A2 (pt) | composições pour-on antiparasíticas | |
HU196307B (en) | Process for producing vermicides comprising levamisole-nitroxinil salt | |
CZ20031421A3 (cs) | Stabilní farmaceutická forma léku proti rakovině | |
BR112015014963B1 (pt) | Formulação de suspensão injetável veterinária | |
BR112016020896B1 (pt) | Formulações anti-helmínticas veterinárias estáveis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21878806 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 18031942 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021878806 Country of ref document: EP Effective date: 20230516 |
|
ENP | Entry into the national phase |
Ref document number: 2021361343 Country of ref document: AU Date of ref document: 20211014 Kind code of ref document: A |